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Objectives. The purpose of this study was to report he 3-year 
follow-up results of the ERACI trial (Argentine Randomized Trial 
of Percutaneous Transluminal Coronary Angioplasty Versus Cor- 
onary Artery Bypass Surgery in Multivessel Disease). 
Background. Although coronary angioplasty has been used with 
increased frequency in patients with multivessel coronary artery 
disease, its value, compared with bypass graft surgery, has not 
been established. Thus, controlled, randomized clinical trials such 
as the ERACI are needed. 
Methods. In this trial 127 patients who had multivessel coro- 
nary artery disease and clinical indication of myocardial revascu- 
larization were randomized to undergo coronary angioplasty (n = 
63) or bypass urgery (n = 64). The primary end point of this 
study was event-free survival (survival with freedom from myo- 
cardial infarction, angina and new revascularization procedures) 
for both groups of patients at 1, 3 and 5 years of follow-up. 
Results. Freedom from combined cardiac events (death, Q-wave 
myocardial infarction, angina and repeat revascnlarization pro- 
cedures) was significantly greater for the bypass urgery group 
than the coronary angioplasty group (77% vs. 47%; p < 0.001). 
There were no differences in overall (4.7% vs. 9.5%; p = 0.5) and 
cardiac (4.7% vs. 4.7%; p = 1) mortality or in the frequency of 
myocardial infarction (7.8% vs. 7.8%; p = 0.8) between the two 
groups. However, patients who had bypass surgery were more 
frequently free of angina (79% vs. 57%; p < 0.001) and required 
fewer additional reinterventions (6.3% vs. 37%; p < 0.001) than 
patients who had coronary angioplasty. 
Conclusions. 1) Freedom from combined cardiac events at 
3-year follow-up was greater in patients who had bypass urgery 
than in those who had coronary angioplasty. 2) The coronary 
angioplasty group had a higher incidence of recurrence ofangina 
and the need for repeat revascularization procedures. 3) Cumu- 
lative cost at 3-year follow-up was greater for the bypass urgery 
group than for the coronary angioplasty group. 
(J Am Coll Cardiol 1996;27:1178-84) 
Coronary artery bypass graft surgery and percutaneous trans- 
luminal coronary angioplasty are the most commonly used 
procedures to treat patients with coronary artery disease who 
require myocardial revascularization. Bypass surgery has been 
demonstrated to be effective in relieving angina, prolonging 
survival and decreasing coronary events in patients with mul- 
tiple vessel disease (1,2). Although coronary angioplasty has 
been used with increased frequency with high success rates and 
low complications in patients with multivessel coronary artery 
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disease (3-8), its value, as compared with bypass urgery, has 
not been established. Several controlled, randomized clinical 
trials of coronary angioplasty versus bypass urgery in patients 
with multivessel coronary artery disease in North and South 
America nd Europe have reported their partial or final results 
(9-14). We previously reported the immediate and first-year 
follow-up results of the ERACI (Argentine Randomized Trial 
of Percutaneous Transluminal Coronary Angioplasty Versus 
Coronary Artery Bypass Surgery in Multivessel Disease) pa- 
tients who were considered good candidates for either proce- 
dure (9). In the present study we report the 3-year clinical 
follow-up of these patients. 
Methods  
Patients. Details of the ERACI trial have been previously 
described (9). This trial included patients with multivessel 
coronary artery disease and clinical indication of myocardial 
revascularization in whom complete functional revasculariza- 
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tion could be achieved by the treatment of coronary lesions 
amenable to both coronary angioplasty or bypass urgery. The 
patients were required to have ->70% stenosis in more than 
one major epicardial coronary artery. Patients with severe 
main left trunk stenosis, poor left ventricular ejection fraction 
(-<35%), associated severe valvular or hypertrophic heart 
disease, or both, evolving acute myocardial infarction and 
limited life expectancy were excluded from the study (9). The 
primary end point of this study was to compare event-free 
survival (survival with freedom from myocardial infarction, 
angina and new revascularization procedures) between both 
groups of patients at 1, 3, and 5 years of follow-up. Secondary 
end points included 1) comparison of major in-hospital com- 
plications (death, Q-wave myocardial infarction and emer- 
gency revascularization procedures); 2) comparison of the 
completeness of revascularization asachieved by both meth- 
ods; and 3) comparison of in-hospital and late costs of both 
revascularization techniques. 
Of 1,409 patients with a presumptive clinical diagnosis of 
coronary artery disease who underwent coronary arteriography 
at the Anchorena Hospital between June 1988 and December 
1990, revascularization was indicated in 748 patients. Entrance 
criteria for randomization were met by 302 patients. Of these 
302 patients, 63 were randomized to coronary angioplasty and 
64 to bypass urgery. Of the 175 patients with randomizable 
criteria but who were not randomized, 99 had coronary 
angioplasty and 76 had bypass urgery. The randomized group 
included 108 males and 19 females with a mean age of 58 + 5 
years (range 33 to 76). The two randomized groups (bypass 
surgery and coronary angioplasty) were well matched for 
demographic, linical, arteriographic and angiographic charac- 
teristics. There were no significant differences in the number of 
double (53.1% vs. 57.1%) and triple (46.9% vs. 42.9%) vessels 
or in left ventricular ejection fraction (62 _+ 12% vs. 59 _+ 12%) 
between the two groups (9). The major in-hospital com- 
plications and follow-up events of both revascularization 
modalities--mortality, Q-wave myocardial infarction, inci- 
dence of angina and the need for additional revascularization 
procedures (coronary angioplasty or bypass surgery)--were 
recorded. A trained staff was responsible for data collection of 
variables and clinical follow-up of patients (using tabulated 
forms). Patients were contacted every 6 months for follow-up 
information. The organization and analysis of the results of the 
study were conducted by a central coordinating executive 
committee. The study was monitored by a Safety and Data 
Monitoring Committee. 
Statistical analysis. Continuous variables are expressed as 
mean _+ SD. Differences in categorical variables between both 
groups of patients were determined using chi-square analysis. 
The Student test or Wilcoxon two-sample test was used for 
comparison of continuous variables when appropriate. Overall 
survival and survival with freedom from combined cardiac 
events for both groups of patients at 3-year follow-up were 
determined using Kaplan-Meier curves and the log-rank test. 
A p value <0.05 was considered statistically significant. As 
previously reported, the power of this study (estimating a
combined event-free survival at 1, 3 and 5 years of follow-up of 
75% to 85% in the bypass urgery group and 55% to 65% for 
the coronary angioplasty group) is 70% (9). 
Resu l ts  
Initial and 1-year follow-up. The baseline clinical and 
angiographic haracteristics and the in-hospital and 1-year 
follow-up results of the ERACI trial were previously reported 
(9). Coronary angioplasty and bypass urgery were associated 
with similar rates of in-hospital mortality (1.5% in coronary 
angioplasty vs. 4.6% in bypass urgery), periprocedural Q-wave 
myocardial infarction (6% in coronary angioplasty vs. 6% in 
bypass surgery) and incidence of urgent revascularization 
(1.5% in coronary angioplasty vs. 1.5% in bypass urgery). At 
1-year follow-up there were no significant differences in mor- 
tality and incidence of Q-wave myocardial infarction between 
the two groups. However, patients who had bypass surgery 
were more frequently free of angina and were less likely to 
need additional revascularization procedures. 
Mortality. In the bypass surgery group, three patients 
(4.7%) died during the 3 years of follow-up. All of deaths from 
bypass urgery occurred uring the initial hospitalization and 
none occurred uring the follow-up period. 
In the coronary angioplasty group, six patients (9.5%) died 
during the 3 years of follow-up. There were three cardiac 
(4.7%) and three noncardiac (4.7%) deaths. One cardiac death 
occurred during the initial hospitalization. Two additional 
cardiac deaths occurred uring the follow-up eriod. The three 
noncardiac deaths included one patient who had undergone 
bypass urgery 2months after coronary angioplasty and died of 
lung cancer at the beginning of the second year of follow-up; 
one patient maintained on long-term dialysis who died from 
meningitis; and one patient who died in an automobile acci- 
dent. 
There were nonsignificant differences in overall (4.7% vs. 
9.5% for bypass urgery and coronary angioplasty, respectively; 
p = 0.5) and cardiac (4.7% vs. 4.7% for bypass urgery and 
coronary angioplasty, respectively; p = 1) mortality between 
the coronary angioplasty and the bypass urgery groups. The 
corresponding actuarial survival curves during the 3 years of 
follow-up for these two groups of patients are shown in the 
right upper panel of Figure 1. 
Q-wave myocardial infarction. In the bypass urgery group, 
five patients (7.8%) sustained a new nonfatal Q-wave myocar- 
dial infarction within the 3 years of follow-up, with three of 
them occurring during the initial hospitalization. 
In the coronary angioplasty group, five patients (7.8%) 
sustained a new nonfatal Q-wave myocardial infarction within 
the 3 years of follow-up, with three of them occurring during 
the initial hospitalization. 
There was no significant difference in the incidence of new 
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Figure 1. Comparison of overall 
survival (upper left), survival with 
freedom from Q-wave myocardial in- 
farction (AMI) (upper right), sur- 
vival with freedom from angina (bot- 
tom left) and survival with freedom 
from combined cardiac events (bot- 
tom right) in patients who had coro- 
nary artery bypass graft surgery 
(CABG) and percutaneous translu- 
minal coronary angioplasty (PTCA). 
nonfatal Q-wave myocardial infarction between the coronary 
angioplasty group and the bypass urgery group (7.8% vs. 7.8% 
for bypass urgery and coronary angioplasty, respectively; p = 
0.8). The corresponding actuarial survival with freedom from 
nonfatal Q-wave myocardial infarction curves during the 3 
years of follow-up for these two groups of patients is shown in 
the left upper panel of Figure 1. 
Event-free survival (end point). As shown in the left lower 
panels of Figure 1, the 3-year actuarial event-free survival 
(survival with freedom from nonfatal Q-wave myocardial in- 
farction, angina and repeat revascularization procedures) was 
significantly greater in the bypass urgery group than in the 
coronary angioplasty group (77% vs. 47% for bypass urgery 
and coronary angioplasty, respectively; p < 0.0005). As shown 
in the right lower panel of Figure 1, the 3-year actuarial 
survival with freedom from angina (79% vs. 56.5% for bypass 
surgery and coronary angioplasty, respectively; p < 0.001) was 
significantly greater for the bypass urgery group. Patients who 
had coronary angioplasty had both a higher incidence of 
angina (43% vs. 21%; p < 0.001) and a greater need for repeat 
revascularization procedures (37% vs. 6.3%; p < 0.001) than 
those who had bypass urgery. 
When considering the coronary angioplasty group alone, 
there were nonsignificant differences in freedom from com- 
bined cardiac events between those patients in whom coronary 
angioplasty resulted in "complete anatomic revascularization" 
and those in whom coronary angioplasty resulted in "complete 
functional revascularization." 
Incidence of angina. Eleven patients in the bypass urgery 
group (18%) and 24 patients in the coronary angioplasty group 
(39%) had angina at the end of the first year. 
Although the prevalence of angina was significantly higher 
in the coronary angioplasty group during the initial 6 months of 
follow-up, this difference disappeared by the end of the third 
year of follow-up (4.8% for coronary angioplasty vs. 3.2% for 
bypass urgery; p = NS). 
Repeat revascularization procedures. A total of 23 pa- 
tients (37%) in the coronary angioplasty group and four 
patients (6.3%) in the bypass surgery group underwent a 
second revascularization procedure (coronary angioplasty or 
bypass urgery) during the 3 years of follow-up. In the first year 
of follow-up, 20 of the patients in the coronary angioplasty 
group underwent a second revascularization procedure (9 
repeat angioplasties and 11 bypass urgeries)within 6 months 
of randomization. Three additional patients in the coronary 
angioplasty group underwent bypass urgery during the second 
and third years of follow-up. 
Meanwhile, only three additional patients in the bypass 
surgery group required a repeat revascularization procedure 
during the 3 years of follow-up. Coronary angioplasty was 
performed in two of these patients in the first year of follow-up 
and in one other patient during the rest of the follow-up 
period. There was a significant difference in the incidence of 
repeat revascularization procedures between the coronary angio- 
plasty and the bypass urgery groups (37% vs. 6.3% for coronary 
angioplasty and bypass urgery, respectively; p < 0.001). 
Hospital cost. Table 1 summarizes the cost of revascular- 
ization procedures for both groups of patients. An estimate of 
hospital cost per patient for both procedures was calculated 
using the payment (in U.S. currency) established by the 
medical system of Argentina ($4,000 and $5,000 for noncom- 
plex and complex coronary angioplasty, respectively vs. $12,000 
and $15,000 for noncomplex and complex bypass surgery, 
respectively). The estimated hospital cost for the 63 patients 
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Table 1. Cost of Revascularization Procedures 
PTCA CABG p 
(n = 63) (n = 64) Value 
In hospital $270,000 $820,000 0.01 
Three-year follow-up* $204,000 $12,000 0.01 
Total $474,000 $832,000 0.02 
*Includes only repeat revascularization procedures: coronary artery bypass 
graft surgery (CABG) or percutaneous transluminal coronary angioplasty 
(PTCA). 
who had coronary angioplasty, including the in-hospital com- 
plications (one emergency bypass urgery), was $270,000. The 
estimated hospital cost for the 64 patients who had bypass 
surgery (52 noncomplex and 12 complex) was $820,000 (p = 
0.01). During the 3-year follow-up, 9 coronary angioplasties 
and 14 bypass surgeries were performed in the coronary 
angioplasty group because of restenosis. This implies an addi- 
tional estimated cost of $204,000 to the initial hospital cost of 
the coronary angioplasty cohort. Therefore, the total estimated 
cost of patients treated with coronary angioplasty (in-hospital 
and 3-year follow-up) was of $474,000. However, in the bypass 
surgery group, two patients underwent coronary angioplasty 
during the first year of follow-up and one patient during the 
rest of the follow-up, adding $12,000 to the initial hospital cost. 
Thus, the total cost of patients who had bypass surgery 
(in-hospital and 3-year follow-up) of $832,000 was significantly 
higher than the cost of patients who had coronary angioplasty 
of $474,000 (p : 0.02). 
Patients with randomizable criteria but who were not 
randomized. As we previously described (9), 175 patients had 
criteria of randomization but were not randomized--99 were 
treated with coronary angioplasty and 76 with bypass urgery. 
The immediate and long-term results of this group of patients 
are shown in Table 2. Patients who had bypass urgery had a 
Table 2. Immediate and Follow-Up Results of Nonrandomized 
("registry") Patients 
CABG PTCA 
(n : 76) (n : 99) 
Three-vessel CAD 52.7% 33% 
In-hospital complications 
Mortality 5.2% 2% 
Q-wave MI 3.9% 5% 
Emergency CABG - -  2% 
Stroke 2.6% 0% 
Follow-up results (3 yr) 
Cardiac mortality 0% 2% 
Noncardiac mortality, 2.6% 0% 
Q-wave MI 0% 1% 
Angina (1 yr) 7.1% 20.4% 
Angina (3 yr) 7.1% 12.2% 
Repeat revascularization 0% 28.4% 
CAD = coronary artery disease; MI = myocardial infarction; other abbre- 
viations as in Table 1. 
higher incidence of three-vessel coronary artery disease than 
patients who had coronary angioplasty (52.7% vs. 33%, respec- 
tively). Major in-hospital complications of this cohort of pa- 
tients with criteria of randomization but who were not ran- 
domized included an in-hospital mortality rate of 2% for the 
coronary angioplasty group and 5.2% for the bypass urgery 
group and an incidence rate of periprocedure Q-wave myocar- 
dial infarction of 5% for the coronary angioplasty group and 
3.9% for the bypass surgery group. The incidence rate of 
emergency bypass urgery with coronary angioplasty was 2%. 
There were no strokes in the coronary angioplasty group and 
two strokes (2.6%) in the bypass urgery group. During the 
3-year follow-up of patients with randomizable criteria but who 
were not randomized, no one died during the first year in 
either group. At the end of the 3 years of follow-up, the 
coronary angioplasty cardiac mortality rate was 2%. Although 
there were no additional cardiac deaths in the bypass urgery 
group during the rest of the follow-up eriod, there was a 2.6% 
noncardiac mortality rate in this patient cohort by the end of 
the 3-year follow-up. Nonfatal Q-wave myocardial infarction 
occurred in 1% of the patients who had coronary angioplasty 
and in none of the patients who had bypass urgery during the 
3-year follow-up. During the first year of follow-up, 20.4% of 
the patients who had coronary angioplasty and 7.1% of the 
patients who had bypass urgery developed angina. At the end 
of the 3-year follow-up, angina was present in 12.2% of the 
patients who had coronary angioplasty and in 7.1% of the 
patients who had bypass surgery. Repeat revascularization 
procedures were required in 28.4% of the coronary angioplasty 
group (50% needed another coronary angioplasty and 50% 
needed bypass surgery) and in none of the patients in the 
bypass urgery group. 
Discuss ion  
A 3-year follow-up of the ERACI trial (a randomized study 
of coronary angioplasty versus bypass urgery in the treatment 
of patients with multiple vessel disease and a high prevalence 
of unstable angina) showed a greater event-free survival for 
patients treated with bypass urgery than for those treated with 
coronary angioplasty (77% vs. 47%, respectively). Because 
there were no significant differences in overall survival and 
survival with freedom from nonfatal Q-wave myocardial infarc- 
tion between both groups of patients, this difference is solely 
the result of a higher incidence of recurrence of angina and the 
need for additional revascularization procedures in the coro- 
nary angioplasty group. Furthermore, this study showed that 
the cost (according to the modules of practices of the Social 
Security System of Argentina) at 3-year follow-up, including 
the new revascularization requirements, was significantly 
higher for the cohort of patients who underwent bypass urgery 
than for those who underwent coronary angioplasty. 
Prevalence of angina at follow-up. Patients who had bypass 
surgery were more frequently free of angina during follow-up 
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than those who had coronary angioplasty (79% vs. 57%, 
respectively). The rate of angina in the coronary angioplasty 
group was higher during the first year of follow-up (39% vs. 
18% for coronary angioplasty and bypass urgery, respective- 
ly), reflecting restenosis and incomplete revascularization in 
the coronary angioplasty group. However, this difference is 
attenuated during later follow-up, so that by the end of the 
third year of follow-up the prevalence of angina was similar in 
both groups of patients--a consequence of both a higher ate 
of additional coronary revascularization procedures during the 
follow-up period in the coronary angioplasty group (37% vs. 
6.3% for coronary angioplasty and bypass surgery, respec- 
tively) and graft disease in the bypass surgery group. During 
follow-up, 22% of the patients who initially underwent coro- 
nary angioplasty later needed bypass surgery, whereas only 
6.3% of the patients who initially underwent bypass surgery 
later needed coronary angioplasty. With coronary angioplasty 
there is a high incidence of early events owing to restenosis and 
repeat revascularization procedures; however, with bypass 
surgery there is a low incidence of early events but a significant 
incidence of late events owing to graft disease. Therefore, 
longer follow-up studies are required. 
The completeness of myocardial revascularization achieved 
during bypass urgery in patients with multiple vessel disease is 
an important determinant of the incidence of cardiac events at 
follow-up (15-19). However, the impact of incomplete revas- 
cularization in patients with multiple vessel coronary artery 
disease treated with coronary angioplasty has not been well 
established. Incomplete angiographic revascularization is part 
of the strategy in patients with multiple vessel disease under- 
going coronary angioplasty of the culprit lesions. As we 
reported previously, "incomplete anatomic revascularization" 
resulting from the presence of total chronic occlusions was 
greater in the coronary angioplasty group than in the bypass 
surgery group. However, "complete functional revasculariza- 
tion" was similar in both groups of patients (9). Because the 
event-free survival was similar in the coronary angioplasty 
group of patients with "complete anatomic" rcvascularization 
and in those with "complete functional revascularization," it 
remains unknown whether evascularization f total chronic 
occlusions of vessels irrigating areas of nonviable myocardium 
is necessary when treating patients with multiple vessel disease 
with coronary angioplasty. 
Other randomized trials of coronary angioplasty versus 
bypass surgery for multiple-vessel coronary artery disease. 
The results of our study arc in agreement with those of other 
controlled randomized trials of coronary angioplasty versus 
bypass urgery in patients with multiple vessel disease (10-14). 
Although there are important differences in the design and end 
points in these trials, their results have shown nonsignificant 
differences in in-hospital complications (mortality and Q-wave 
myocardial infarction) and no significant differences insurvival 
and incidence of nonfatal myocardial infarction at follow-up. 
However, compared with patients undergoing bypass urgery, 
those undergoing coronary angioplasty were more likely to 
have angina nd to undergo additional coronary revasculariza- 
tion procedures at follow-up. Our 3-year follow-up results of 
6.3% versus 37% of repeat revascularization f rbypass urgery 
and coronary angioplasty, respectively, are similar to those 
reported by the Randomized Intervention Treatment of An- 
gina (RITA) at 2.5-year follow-up in 1,011 patients (11% vs. 
38%); the German Angioplasty Bypass Investigation (GABI) 
at 1-year follow-up in 359 patients (6.7% vs. 46.5%); the 
Emory Angioplasty Surgery Trial (EAST) at 3-year follow-up 
in 392 patients (13% vs. 54%); and the Coronary Artery Bypass 
Revascularization Investigation (CABRI) at 1-year follow-up 
in 1,054 patients (3.5% vs. 36.5%). The results of the National 
Heart, Lung, and Blood Institute (NHLBI)-sponsored Bypass 
Angioplasty Revascularization Investigation (BARI) in > 1,800 
patients will not be available until completion of the 5-year 
follow-up period. 
Furthermore, similar to these randomized trials (10-14), in 
our study the randomized patients represent only a small 
proportion of the total number of patients who were screened 
for the study. Many patients with multivessel disease are not 
candidates for coronary angioplasty because of significant left 
main coronary artery stenosis, chronic occlusions, complex 
anatomy or diffuse disease. However, other important infor- 
mation can be derived from those patients with criteria of 
randomization but who were not randomized. The in-hospital 
and 3-year follow-up results of our 175 patients with criteria of 
randomization but who were not randomized are similar to 
those of our randomized patients. These results further sup- 
port our findings that the initial form of revascularization, 
either coronary angioplasty or bypass urgery, does not affect 
the prognosis of patients with multivessel disease who have 
lesions that are suitable to treatment with bypass surgery or 
coronary angioplasty. The lack of significant differences in 
mortality and incidence of myocardial infarction between the 
two forms of revascularization demonstrates that the prognosis 
of both techniques is similar in patients with multivessel 
coronary artery disease suitable to treatment with either 
coronary angioplasty or bypass surgery. Although clearly a 
difference xists between the two forms of revascularization n 
terms of angina and repeat revascularization procedures, the 
selection of the revascularization strategy should be deter- 
mined by the patient and the clinician, the available facilities 
and the cost of the procedure. Although coronary angioplasty 
is less expensive initially, the additional revascularization pro- 
cedures in patients who had coronary angioplasty decrease the 
cost advantage of coronary angioplasty at follow-up. In our 
study the cumulative cost (according to the modules of prac- 
tices of the Social Security System of Argentina) at 3-year 
follow-up, including the new revascularization requirements, 
was significantly higher for the bypass urgery group than for 
the coronary angioplasty group. 
Study limitations. As we previously cited, our study sample 
size is small but appropriate to reach our primary aim of 
comparing bypass urgery and coronary angioplasty in patients 
with multiple vessel disease who needed revascularization. The 
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results reported by other randomized studies with a larger 
number of patients, uch as EAST, RITA, GABI and CABRI, 
are in agreement with the results of our study (10-14). 
A higher incidence of unstable angina was present in the 
patients in our study. It has been well established that in- 
hospital complications and the incidence of restenosis after 
angioplasty are greater in patients with unstable angina (20- 
23). Thus, it is possible that results could be different when 
comparing patients with chronic stable angina. 
Our discussion of cost actually is an estimate rather than 
total cost and is based on flat rates for both initial and 
follow-up procedures. Other incurred costs, including physi- 
cian visits, clinic visits, hospital admissions, medications, use of 
multiple catheters, physician fees and the level of disability and 
return to work, were not included in the cost analysis. Al- 
though the cost of medical therapy and more intensive 
follow-up in the patients with recurrent ischemia would need 
to be added to the cost of each group, we do not believe that 
the total cost of the coronary angioplasty group will come close 
to the bypass urgery group. It will be interesting tosee if they 
are close at the 5-year follow-up. 
Finally, in our study, percutaneous revascularization was 
achieved by the use of balloon angioplasty only. The use of the 
second generation of interventional devices that produce de- 
bulking and scaffolding of the coronary stenosis increase the 
success rate, decrease the incidence of acute complications and 
decrease the incidence of restenosis in the coronary angio- 
plasty group (24-33). Thus, further studies are necessary to 
compare coronary artery bypass graft surgery with percutane- 
ous catheter revascularization using coronary angioplasty and 
the second generation of interventional devices. 
We thank Jose Luis Palazzo, MD and the Anchorena Foundation for their 
support. 
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